KR102861339B1 - 삼치환 벤조트리아졸 유도체의 사용 방법 - Google Patents

삼치환 벤조트리아졸 유도체의 사용 방법

Info

Publication number
KR102861339B1
KR102861339B1 KR1020207024137A KR20207024137A KR102861339B1 KR 102861339 B1 KR102861339 B1 KR 102861339B1 KR 1020207024137 A KR1020207024137 A KR 1020207024137A KR 20207024137 A KR20207024137 A KR 20207024137A KR 102861339 B1 KR102861339 B1 KR 102861339B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
composition according
cell lymphoma
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207024137A
Other languages
English (en)
Korean (ko)
Other versions
KR20200123137A (ko
Inventor
다니엘 울라넷
성 은 최
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20200123137A publication Critical patent/KR20200123137A/ko
Application granted granted Critical
Publication of KR102861339B1 publication Critical patent/KR102861339B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207024137A 2018-02-20 2019-02-19 삼치환 벤조트리아졸 유도체의 사용 방법 Active KR102861339B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20
USPCT/US2018/018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Publications (2)

Publication Number Publication Date
KR20200123137A KR20200123137A (ko) 2020-10-28
KR102861339B1 true KR102861339B1 (ko) 2025-09-19

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024137A Active KR102861339B1 (ko) 2018-02-20 2019-02-19 삼치환 벤조트리아졸 유도체의 사용 방법

Country Status (13)

Country Link
US (2) US11717512B2 (https=)
EP (1) EP3755324B1 (https=)
JP (2) JP7434185B2 (https=)
KR (1) KR102861339B1 (https=)
CN (1) CN111757731B (https=)
AU (1) AU2019223906B2 (https=)
BR (1) BR112020016929A8 (https=)
CA (1) CA3091792A1 (https=)
ES (1) ES3038736T3 (https=)
MA (1) MA51897A (https=)
MX (1) MX2020008678A (https=)
TW (1) TWI818954B (https=)
WO (1) WO2019164794A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7652051B2 (en) * 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2008028860A1 (en) 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11730716B2 (en) 2014-05-08 2023-08-22 Kiora Pharmaceuticals Gmbh Compounds for treating ophthalmic diseases and disorders
US11096934B2 (en) 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
WO2020109625A1 (en) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
US12582667B2 (en) 2019-09-27 2026-03-24 The Rockefeller University Compositions and methods to treat metastatic gastrointestinal cancer
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) * 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors

Also Published As

Publication number Publication date
CA3091792A1 (en) 2019-08-29
MA51897A (fr) 2020-12-30
ES3038736T3 (en) 2025-10-14
BR112020016929A2 (pt) 2020-12-15
EP3755324B1 (en) 2025-07-30
JP2023109974A (ja) 2023-08-08
CN111757731B (zh) 2024-06-25
BR112020016929A8 (pt) 2022-06-28
TW201938543A (zh) 2019-10-01
EP3755324C0 (en) 2025-07-30
US12290508B2 (en) 2025-05-06
CN111757731A (zh) 2020-10-09
AU2019223906B2 (en) 2024-11-21
US20240148697A1 (en) 2024-05-09
US11717512B2 (en) 2023-08-08
JP7434185B2 (ja) 2024-02-20
WO2019164794A1 (en) 2019-08-29
EP3755324A1 (en) 2020-12-30
AU2019223906A1 (en) 2020-09-10
MX2020008678A (es) 2020-09-25
JP2021514395A (ja) 2021-06-10
US20210113531A1 (en) 2021-04-22
KR20200123137A (ko) 2020-10-28
TWI818954B (zh) 2023-10-21

Similar Documents

Publication Publication Date Title
KR102861339B1 (ko) 삼치환 벤조트리아졸 유도체의 사용 방법
JP2020517652A (ja) 併用療法
CN106660991A (zh) 抗增殖化合物及其使用方法
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
TW202329969A (zh) 用於治療急性髓系白血病的ＦＬＴ３抑制劑和Ｂｃｌ－３抑制劑的治療有效組合
US20130101680A1 (en) Radiotherapy enhancer
CA2912830A1 (en) Specific cancer treatment regimens with ganetespib
JP2018511642A (ja) 癌を治療するための方法
CN112121052B (zh) 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途
US20260021106A1 (en) Combination therapy for treating cancers
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
AU2006231809B2 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
KR102687556B1 (ko) 종양 전이를 억제하는 방법
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
EP3777852A1 (en) Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
WO2025070603A1 (ja) 血液がんの新規併用療法
HK1118807B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

G15 Pta requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G15-TAD-PA0102 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 96

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 96